KB-1158

Theralizumab

52664

Home » Theralizumab

Background of Theralizumab

The CD28 molecule is a member of the Ig superfamily and is expressed as a homodimer composed of two peptide chains on the surface of CD4+ T cells and more than half of CD8+ T cells. Theralizumab(TGN1412) was a promising therapeutic agent that yielded outstanding results in both in vitro studies and animal trials. It is a CD28 superagonist monoclonal antibody that activates T regulatory (TReg) cells in the absence of costimulation of the T cell receptor (TCR) by an antigen-presenting cell. This drug was intended as a solution to T cell deficient diseases such as B cell leukemia and autoimmune diseases such as rheumatoid arthritis.

Specifications

Catalog Number	KB-1158
Antibody Name	Theralizumab
Isotype	Human IgG4-S228P, kappa
FC Muations	S228P
Target	CD28
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA\|KD
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Dmitry Tyrsin , Sergey Chuvpilo , Alexey Matskevich , Daniil Nemenov , Paula S Römer , Paula Tabares , Thomas Hünig. From TGN1412 to TAB08:the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol.2016 Jul-Aug;34(4 Suppl 98):45-8
Katelyn E Brown . Revisiting CD28 Superagonist TGN1412 as Potential Therapeutic for Pediatric B Cell Leukemia: A Review. Diseases. 2018 May 19;6(2):41.